BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co Total Assets

The Total Assets of BrightGene Bio-Medical Technology Co (688166.SS) as of Nov 22, 2026 is 5.82 B CNY. In the previous year, Total Assets was 5.16 B CNY — a change of 12.79% (higher).

Total Assets

5.82 BCNY

YoY

12.79%

Last updated:

Total Assets of BrightGene Bio-Medical Technology Co is 2025 5.82 B CNY. Total Assets of BrightGene Bio-Medical Technology Co was 2024 5.16 B CNY. It decreases by 12.79% higher compared to the previous year.

The BrightGene Bio-Medical Technology Co Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
878.37 M CNY
Jan 1, 2019
1.42 B CNY
Jan 1, 2020
1.83 B CNY
Jan 1, 2021
2.97 B CNY
Jan 1, 2022
4.66 B CNY
Jan 1, 2023
5.03 B CNY
Jan 1, 2024
5.16 B CNY
Jan 1, 2025
5.82 B CNY
The BrightGene Bio-Medical Technology Co Total Assets history
YEARTotal AssetsYoY
5.82 BCNY+12.79%
5.16 BCNY+2.63%
5.03 BCNY+7.95%
4.66 BCNY+56.97%
2.97 BCNY+62.47%
1.83 BCNY+28.60%
1.42 BCNY+61.81%
878.37 MCNY+67.34%
524.92 MCNY+36.63%
384.19 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

Total Assets of BrightGene Bio-Medical Technology Co is 5.82 B CNY in 2025.

Total Assets of BrightGene Bio-Medical Technology Co changed from 5.16 B CNY to 5.82 B CNY, representing a 12.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's BrightGene Bio-Medical Technology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BrightGene Bio-Medical Technology Co

All Key Metrics — BrightGene Bio-Medical Technology Co